1 / 26

Sandra Ramos Grade A Project St George’s Hospital, London

Analysis of three genes from the RAS-MAPK signalling pathway that are causative of Noonan/LEOPARD syndromes. Sandra Ramos Grade A Project St George’s Hospital, London. Aims of the Project. Extend existing Noonan/LEOPARD syndrome screen to include new genes Test the LightScanner™ (HRM) as a

megara
Download Presentation

Sandra Ramos Grade A Project St George’s Hospital, London

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Analysis of three genes from the RAS-MAPK signalling pathway that are causative of Noonan/LEOPARD syndromes Sandra Ramos Grade A Project St George’s Hospital, London

  2. Aims of the Project • Extend existing Noonan/LEOPARD syndrome screen to include new genes • Test the LightScanner™ (HRM) as a pre-screening tool • Investigate genotype-phenotype correlations • Determine optimal NS/LS future testing strategy

  3. Noonan syndrome (NS) • Autosomal dominant • Incidence of 1 in 1000 to 1 in 2500 • Clinically heterogeneous disorder characterized by: - distinct facial features - short stature - congenital heart defects - skeletal abnormalities - bleeding problems Taken from London Medical Database

  4. LEOPARD syndrome (LS) • Rare autosomal dominant disease • Characterized by: - Lentigines - ECG conduction abnormalities - Ocular hypertelorism - Pulmonary stenosis - Abnormalities of genitalia - Retardation of growth - Deafness Taken from E. J. of Human Genetics (2004) 12, 1069–1072

  5. Molecular Genetics of NS • Caused by missense gain-of-function mutations in RAS-MAPK pathway • ~ 60% of Noonan syndrome cases are sporadic, presumed to be the result of de novo mutations Molecular Genetics of LS • Caused by loss of function/dominant negative mutations affecting the catalytic activity of PTPN11

  6. HRAS KRAS Noonan syndrome MEK LEOPARD syndrome ERK RAS-MAPK Signalling Pathway RTK SOS1 Shc Grb2 Gab2 40 - 50% SHP-2 RAF1 BRAF ~ 90% Transcription of Target Genes

  7. SOS1 gene • SOS1 is located on chromosome 2p22.1 and encodes a major RAS-GEF • Consists of 23 exons of which 9 have reported mutations • Variants disrupt autoinhibition RAS-GEF activity

  8. HRAS KRAS Noonan syndrome MEK LEOPARD syndrome ERK RAS-MAPK Signalling Pathway 5 - 10% RTK SOS1 Shc Grb2 Gab2 SHP-2 RAF1 BRAF Transcription of Target Genes

  9. KRAS gene • KRAS is located on chromosome 12p12.1 • Encodes a small G protein that is activated by the exchange of bound GDP for GTP • Consists of six exons but RNA splicing reveals two different transcripts • in 98% of transcripts exon 4a is spliced out and exon 4b is translated into protein

  10. HRAS KRAS Noonan syndrome MEK LEOPARD syndrome ERK RAS-MAPK Signalling Pathway RTK ~ 1% SOS1 Shc Grb2 Gab2 SHP-2 RAF1 BRAF Transcription of Target Genes

  11. RAF1 gene • RAF1 is located on chromosome 3p25 and encodes serine-threonine protein kinase that activates MEK1 and MEK2. • Consists of 17 exons of which 3 have reported mutations • Mutations alter autoinhibition of RAF1

  12. HRAS KRAS Noonan syndrome MEK LEOPARD syndrome ERK RAS-MAPK Signalling Pathway RTK SOS1 Shc Grb2 Gab2 3 - 8% SHP-2 RAF1 BRAF Transcription of Target Genes

  13. WAVE v LightScanner™ • Primers designed using LightScanner™ primer design software • CADAMA HotShot mastermix • Idaho Technologies designed Touchdown PCR program • Amplified products were successfully analysed using dHPLC (WAVE) and bidirectional sequencing (ABI3730) SOS1 primers

  14. WAVE v LightScanner™ results SOS1 exon 13 LS trace SOS1 exon 13 WAVE trace LightScanner™ software missed SOS1 exon 13 variant control (black arrow) Wave traces for SOS1 exon 13 normal samples and 1 variant control (black arrow)

  15. WAVE v LightScanner™ results SOS1 exon 10 LS trace SOS1 exon 10 WAVE trace Visual checks difficult by the lack of uniformity/normalisation in traces

  16. WAVE v LightScanner™ results SOS1 exon 16 variant control only detected when sensitivity is increased to 2.40

  17. WAVE v LightScanner™ conclusions

  18. Testing • Cohort of 110 patients from SEEGEN region referred for NS/LS testing • All negative for PTPN11 mutations • Screened exons with reported mutations only • - SOS1 – 9 Exons (3,6,7,8,10,11,13,14 & 16) • - RAF1 – 3 Exons (6,13 & 16) • - KRAS – 5 Exons (1,2,3,4a & 4b) • Samples pre-screened on the Transgenomic WAVE and variants sequenced using ABI3730

  19. Results 110 patients screened for SOS1, RAF1 and KRAS SOS1 • 7 missense variants identified of which • 5 previously reported mutations • and • 2 novel missense variants • The prevalence of SOS1 mutations found is 6.4% RAF1 • 4 missense variants identified of which • 3 previously reported mutations • and • 1 novel missense variant • The prevalence of RAF1 mutations found is 3.7% • No mutations found in KRAS gene

  20. Genotype-Phenotype Clinical features of NS individuals with SOS1 mutations VSD/ASD (Ventriculal/Atrial septal defect); PVS (Pulmonary valve stenosis); LD (learning difficulties)

  21. Genotype-Phenotype Clinical features of NS/LS individuals with RAF1 mutations HOCM (Hypertrophic obstructive cardiomyopathy); PS (Pulmonary stenosis); LD (learning difficulties)

  22. SOS1 Mutations RAF1 Mutations Genotype-phenotype

  23. Logging-in / Extraction NS/LS Testing Strategy • STAGE 1 • dHPLC analysis of exons 2, 3, 4, 7, 8, 12 and 13 of PTPN11 • Bidirectional Sequencing of variants (ABI 3730) ~ 40-50% NS cases ~ 90% LS cases ~ 10 % NS cases Exceptional LS cases • STAGE 2 • dHPLC analysis of exons 3, 6, 10 of SOS1 and 6, 13, 16 of RAF1 • Bidirectional Sequencing of variants (ABI 3730) STAGE 3 • dHPLC analysis of remaining exons of SOS1 and all exons of KRAS • Bidirectional Sequencing of variants (ABI 3730) ~ 1-3 % NS cases

  24. Conclusions • Three genes analysed and 9 mutations (plus 3 novel variants) detected in SOS1/RAF1 from 110 samples • Overall pick up rate for our cohort is ~10% • No mutations identified in KRAS • dHPLC WAVE is a more robust pre-screening method compared to LightScanner™ HRM • Complex genotype-phenotype correlation • Three stage screening strategy designed for NS/LS referrals from April 2008

  25. Further Work Taken fromEMBO reports 6, 12, 1169–1175 (2005)

  26. Acknowledgements Thank you: • John Short • Navaratnam Elanko • Roy Poh • Sally Cottrell • Rohan Taylor • Professor Michael Patton • Kamini Kalidas (Clinical Developmental Sciences, St George’s University of London) • IDEAS Knowledge Park for funding this project and all staff at Molecular Genetics Lab at St George’s

More Related